$PGEN News

HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $14

Precigen Says FDA Grants Orphan Drug Exclusivity For PAPZIMEOS For Treatment Of Adults With Recurrent Respiratory Papillomatosis

Precigen: Why I Am More Cautious After The Q1 Beat (Downgrade)

Citizens Maintains Market Outperform on Precigen, Raises Price Target to $11

HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $11

Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript

Transcript: Precigen Q1 2026 Earnings Conference Call

Precigen Q1 EPS $(0.02), Inline, Sales $23.252M Beat $20.800M Estimate

Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13

Is Precigen, Inc. (PGEN) A Good Stock To Buy Now?

Is Precigen Inc. (PGEN) The Best Healthcare Penny Stock to Buy?

Wall Street Bullish on ​Precigen (PGEN) As the Company Transitions to Commercial Stage

Precigen Sees Strong Early Demand for New Immunotherapy Since Launch, CMS Reimbursement Code Boosts Access as Sales Expected to Top $18M

Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript

Precigen: The Best Potential Blockbuster You've Never Heard Of (Your ENT Has)

These Analysts Boost Their Forecasts On Precigen Following Q4 Results

Citizens Maintains Market Outperform on Precigen, Raises Price Target to $9

HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $10

Precigen shares are trading higher after the company reported better-than-expected Q4 EPS results.

Precigen shares are trading higher after the company reported better-than-expected Q4 EPS results.